Vision

How your vision can predict dementia 12 years before it is diagnosed – new study

Retrieved on: 
Wednesday, April 10, 2024

Our latest study shows that a loss of visual sensitivity can predict dementia 12 years before it is diagnosed.

Key Points: 
  • Our latest study shows that a loss of visual sensitivity can predict dementia 12 years before it is diagnosed.
  • Our research was based on 8,623 healthy people in Norfolk, England, who were followed up for many years.
  • By the end of the study, 537 participants had developed dementia, so we could see what factors might have preceded this diagnosis.
  • People who would develop dementia were much slower to see this triangle on the screen than people who would remain without dementia.

Recognising faces

  • We have some evidence which suggests that people with dementia tend to process new people’s faces inefficiently.
  • In other words, they don’t follow the usual pattern of scanning the face of the person they are talking to.
  • So this early issue in not recognising people you have just met could be related to ineffective eye movement for new faces, rather than being a pure memory disorder.

Can eye movement improve memory?

  • Previous research on the matter is mixed, but some studies found that eye movement can improve memory.
  • In other studies, eye movements from left to right and right to left done quickly (two eye movements per second) were found to improve autobiographical memory (your life story).
  • Also, using deficits in eye movements as a diagnostic is not a regular feature, despite the possibilities in eye movement technology.


Eef Hogervorst receives funding from the Dunhill Medical Trust [email protected] receives funding from Road Safety Trust. He is affiliated with Applied Vision Association. Ahmet Begde does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

I-RES and Vision enter into a Co-Operation Agreement

Retrieved on: 
Wednesday, April 10, 2024

The resolutions put forward by Vision on 20 March 2024 for inclusion in the Company’s Notice of AGM have been withdrawn.

Key Points: 
  • The resolutions put forward by Vision on 20 March 2024 for inclusion in the Company’s Notice of AGM have been withdrawn.
  • Hugh Scott-Barrett, Chairman of the Board I-RES said:
    “The Co-Operation Agreement with Vision provides a constructive framework to address the maximisation of value for shareholders.
  • Jeff Olin, the President & CEO and Portfolio Manager of Vision said:
    "We are pleased with the proposed appointments of Richard Nesbitt and Amy Freedman.
  • For further information please contact:
    For Investor Relations at Irish Residential Properties REIT plc:
    Padraig McKeon, I-RES PR and Communications Tel: + 353 (0) 87 231 2632

Vision Submits Resolutions for Inclusion at I-RES AGM

Retrieved on: 
Wednesday, April 10, 2024

I-RES announces that it has received a request from Vision Capital Corporation (“Vision”) to put a number of resolutions on the agenda for the Company’s annual general meeting (“AGM”), to be held on 2 May 2024.

Key Points: 
  • I-RES announces that it has received a request from Vision Capital Corporation (“Vision”) to put a number of resolutions on the agenda for the Company’s annual general meeting (“AGM”), to be held on 2 May 2024.
  • In its proposals, Vision seeks to have I-RES shareholders fund the costs of its campaign against I-RES of up to €425,000.
  • Vision is also seeking to put forward three nominees for appointment to the Board, all of whom were previously considered and rejected by shareholders at the recent extraordinary general meeting (“EGM”) requisitioned by Vision.
  • Vision has requested that I-RES use shareholders’ funds to cover a significant part of Vision’s activism costs.

Gorilla Reports Record 2023 Financial Results

Retrieved on: 
Thursday, April 4, 2024

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Gorilla Technology Group Inc. (NASDAQ: GRRR) (“Gorilla” or the “Company”), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today reported financial results for the fiscal year ending December 31, 2023.

Key Points: 
  • Profitability Turnaround: Gorilla recorded net profit of $19.9 million in fiscal year 2023, a dramatic shift of 123% from a loss of $(87.5) million in fiscal year 2022.
  • Gorilla, with leading innovation and relentless drive, has not just met our financial targets; we have catapulted beyond them.
  • The Company will host a conference call on Monday, April 8, 2024 at 8:00 AM EDT to discuss the Company's financial results.
  • The following table summarizes financial results (2023, unreviewed and unaudited):

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024

WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update
    WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • During the fourth quarter of 2023, research and development expense increased by $0.1 million from $1.9 million in the fourth quarter of 2022 to $2.0 million.
  • General and administrative expenses decreased by $0.1 million to $1.3 million during the fourth quarter of 2023, from $1.4 million during the fourth quarter of 2022.
  • Yield10 Bioscience management will host a conference call today at 4:30 p.m. (ET) to discuss the fourth quarter and full year 2023 results.

Intel Unleashes Enterprise AI with Gaudi 3, AI Open Systems Strategy and New Customer Wins

Retrieved on: 
Tuesday, April 9, 2024

The Intel Gaudi 3 AI accelerator will power AI systems with up to tens of thousands of accelerators connected through the common standard of Ethernet.

Key Points: 
  • The Intel Gaudi 3 AI accelerator will power AI systems with up to tens of thousands of accelerators connected through the common standard of Ethernet.
  • Intel Gaudi 3 promises 4x more AI compute for BF16 and a 1.5x increase in memory bandwidth over its predecessor.
  • Intel outlined its strategy for open scalable AI systems, including hardware, software, frameworks and tools.
  • In addition to the Intel Gaudi 3 accelerator, Intel provided updates on its next-generation products and services across all segments of enterprise AI.

Wearable Devices XR Team's Report: The Mudra Band Can Be the Neural Bridge for Apple and Meta in their Next Wave of Smart Glasses Interaction

Retrieved on: 
Monday, March 18, 2024

YOKNEAM ILLIT, ISRAEL, March 18, 2024 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI")-powered touchless sensing wearables, published today a comprehensive report by its XR team reviewing the latest developments in the wearable technology market, focusing on extended reality (XR). This comprehensive report draws on extensive research into Human-Computer Interaction (HCI) to present a detailed overview of the innovative strides made by industry leaders such as Apple and Meta, as well as the pioneering role of the company’s Mudra Band in advancing smart glasses technology.

Key Points: 
  • In their report, the XR team from Wearable Devices elucidates the growing dynamism and mainstream appeal of the smart glasses market, notably accelerated by the entrance of major players such as Meta and Apple.
  • The report puts a spotlight on the myriad methods of HCI currently revolutionizing the field of smart glasses.
  • These range from touchless and hands-free interfaces, advanced eye-tracking, to the cutting-edge realms of neural interface wristbands and thought-based brain implants.
  • Wearable Devices’ technology and its flagship product the Mudra Band emerge as a standout innovation.

Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024

BOCA RATON, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the successful launch of its new “Fair Deal Agreement” for the SRT-100 Vision™ (IG-SRT) at the AAD 2024 Annual Meeting, held March 8-12 in San Diego. This meeting is the largest gathering of dermatologists in the U.S., hosting more than 10,000 medical personnel at this year’s event.

Key Points: 
  • This meeting is the largest gathering of dermatologists in the U.S., hosting more than 10,000 medical personnel at this year’s event.
  • Sensus manufactures and sells the only proven, FDA-cleared IG-SRT system and holds a patent for SRT combined with ultrasound, which is deeper and more effective.
  • “The AAD Annual Meeting was the ideal forum to launch our new Fair Deal Agreement program, and the response among conference attendees exceeded our most optimistic expectations.
  • This technology is ideal for better managing dermatology clinical practice, and is a Sensus Healthcare exclusive.

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Retrieved on: 
Wednesday, March 13, 2024

“We are very enthusiastic about the potential of OCU410 as a one-time treatment for life with a single sub-retinal injection,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen.

Key Points: 
  • “We are very enthusiastic about the potential of OCU410 as a one-time treatment for life with a single sub-retinal injection,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen.
  • “While there are currently two recently approved products for the treatment of GA, both require approximately 6-12 intravitreal injections annually and target only the complement system.
  • OCU410 addresses multiple pathways causing dAMD, including complement, lipid metabolism, inflammation, and oxidative stress.”
    Up to 13 leading retinal surgery centers across the United States are participating in the ArMaDa clinical trial.
  • The enrollment in the first cohort is now complete and 3 subjects received 200µL single subretinal administration of the low dose (2.5x1010 vg/mL) of OCU410.

Vision & Voice, an Inclusive Community for Female Cybersecurity Leaders, Announces its Advisory Board

Retrieved on: 
Wednesday, April 3, 2024

Today, Vision & Voice , a nonprofit organization dedicated to empowering the next generation of female leaders in cybersecurity, unveiled its official Advisory Board, a prominent committee of seasoned female professionals.

Key Points: 
  • Today, Vision & Voice , a nonprofit organization dedicated to empowering the next generation of female leaders in cybersecurity, unveiled its official Advisory Board, a prominent committee of seasoned female professionals.
  • The Vision & Voice Advisory Board will help the community’s 600+ members build, fortify and grow each successive generation of female talent entering and ascending in the workforce.
  • Together with the newest members of our advisory board, Vision & Voice remains committed to creating more leadership and growth opportunities for women in cybersecurity professions.”
    The fourteen members of the Vision & Voice Advisory Board represent more than 260 years of business, cybersecurity, and technology industry experience.
  • Our Advisory Board’s mission is to level the playing field for women who want to lead in the cybersecurity industry.